Tevogen Bio Holdings Inc. (TVGN) - Net Assets
Based on the latest financial reports, Tevogen Bio Holdings Inc. (TVGN) has net assets worth $-9.84 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.92 Million) and total liabilities ($14.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TVGN goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-9.84 Million |
| % of Total Assets | -200.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Tevogen Bio Holdings Inc. - Net Assets Trend (2022–2025)
This chart illustrates how Tevogen Bio Holdings Inc.'s net assets have evolved over time, based on quarterly financial data. See Tevogen Bio Holdings Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tevogen Bio Holdings Inc. (2022–2025)
The table below shows the annual net assets of Tevogen Bio Holdings Inc. from 2022 to 2025. For live valuation and market cap data, see how much is Tevogen Bio Holdings Inc. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-6.67 Million | +92.93% |
| 2024-06-30 | $-94.43 Million | -178.13% |
| 2023-06-30 | $-33.95 Million | -105.91% |
| 2022-06-30 | $-16.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tevogen Bio Holdings Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9624646100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.80K | % |
| Other Components | $106.69 Million | % |
| Total Equity | $-6.67 Million | 100.00% |
Tevogen Bio Holdings Inc. Competitors by Market Cap
The table below lists competitors of Tevogen Bio Holdings Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wisher Industrial Co Ltd
TW:1465
|
$40.64 Million |
|
The Berkeley Group Holdings plc
LSE:BKG
|
$40.65 Million |
|
Sunny Elec
KO:004770
|
$40.67 Million |
|
Canterra Minerals Corporation
V:CTM
|
$40.68 Million |
|
Spuntech
TA:SPNTC
|
$40.60 Million |
|
InkTec Co. Ltd
KQ:049550
|
$40.59 Million |
|
Wir Asia Tbk PT
JK:WIRG
|
$40.57 Million |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
$40.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tevogen Bio Holdings Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -94,428,897 to -6,674,005, a change of 87,754,892.
- Net loss of 10,114,380 reduced equity.
- New share issuances of 11,000,000 increased equity.
- Other factors increased equity by 86,869,272.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.11 Million | -151.55% |
| Share Issuances | $11.00 Million | +164.82% |
| Other Changes | $86.87 Million | +1301.61% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Tevogen Bio Holdings Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | $-17.20 | $9.70 | x |
| 2023-06-30 | $-14.15 | $9.70 | x |
| 2024-06-30 | $-28.54 | $9.70 | x |
| 2025-06-30 | $-2.28 | $9.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tevogen Bio Holdings Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.95 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $7.80 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-51.03 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.45 Million |
Industry Comparison
This section compares Tevogen Bio Holdings Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tevogen Bio Holdings Inc. (TVGN) | $-9.84 Million | 0.00% | N/A | $40.62 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 pa… Read more